Montreux Equity Partners
Montreux Equity Partners is a private investment firm dedicated to building the leading healthcare companies of tomorrow.
Business Model:
Revenue: $15.9M
Employees: 51-200
Rankings
Industries / Tags:
Detailed Montreux Equity Partners Information
Geographic Data
Address: 4 Embarcadero Center
City: San Francisco
State: CA
Zip: 94111
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$101M
Social
Linkedin
Crunchbase
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
Founded in 1993, Montreux Equity Partners is a private investment firm focused on making growth capital investments in the leading companies of tomorrow. Our portfolio companies address the most compelling domestic and global trends in health. We are currently investing out of our fifth fund. We focus on commercial stage companies that possess highly differentiated products, technologies, and services. At the time of investment, a company will typically have $5 to $50 million in revenues. Our capital fuels product expansion, new market entry, and strategic acquisitions.
Contact Phone:
+16502341200
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 6/2013 | Colorescience | Series A | 10M |
| 7/2017 | Colorescience | Series C | 15M |
| 7/2012 | Epirus Biopharmaceuticals | Venture Round | 5M |
| 3/2018 | Sonoma Pharmaceuticals | Post-IPO Equity | 4.6M |
| 8/2007 | Tobira Therapeutics | Series A | 31M |
| 4/2005 | NovaCardia | Series A | - |
| 9/2006 | NovaCardia | Series B | 48M |
| 10/2018 | GC Aesthetics | Equity | 97M |
| 4/2014 | SI-BONE | Venture Round | 33M |
| 10/2010 | GC Aesthetics | Venture Round | 30M |
| 4/2014 | Epirus Biopharmaceuticals | Series B | 36M |
| 6/2005 | Verus Pharmaceuticals | Series A | 0 |
| 10/2020 | TigerConnect | Series D | 0 |
| 5/2019 | Crown Laboratories | Private Equity Round | - |
| 3/2002 | PartnerGate | Venture Round | 4M |
| 8/2007 | KFx Medical | Series B | 10M |
| 12/2007 | Pivot Medical | Series B | 0 |
| 9/2003 | Marketwired | Series D | 0 |
| 8/2005 | Cerexa Inc. | Series A | 0 |
| 1/2000 | Cephren | Venture Round | 41.5M |
| 11/1990 | Marketwired | Series A | 17.6M |
| 11/2006 | Avantis Medical Systems | Series B | 12M |
| 12/2003 | Pulmonx | Series A | 7.1M |
| 5/2007 | Pulmonx | Series B | 20M |
| 1/2002 | NeurogesX | Series B | 22.9M |
| 9/2010 | Tobira Therapeutics | Series B | 31M |
| 8/2004 | Avera Pharmaceutical | Series C | 0 |
| 6/2005 | Somaxon Pharmaceuticals | Series C | 0 |
| 4/2000 | StorageWay | Venture Round | 12M |
| 7/2016 | GC Aesthetics | Series D | 0 |
| 7/2022 | Tebra | Series B | 0 |
| 4/2012 | Epirus Biopharmaceuticals | Venture Round | 8.1M |
| 3/2005 | Novalar Pharmaceuticals | Series C | 27M |
| 6/2000 | NeurogesX | Series A | 8.4M |
| 2/2000 | PartnerGate | Series A | 17.5M |
| 12/2005 | NeurogesX | Series D | 20M |
| 3/2022 | FinPay | Series D | 0 |
| 2/2014 | GC Aesthetics | Private Equity Round | 60M |
| 6/2004 | ARYx Therapeutics | Series D | 55M |
| 1/2004 | Peninsula Pharmaceuticals | Series C | 0 |
| 11/2007 | Novalar Pharmaceuticals | Series D | 30M |
| 5/2015 | SI-BONE | Growth | 21M |
| 12/2001 | Marketwired | Venture Round | 0 |
| 5/2005 | Bayhill Therapeutics | Series B | 35.4M |
| 9/2007 | Sequel Pharmaceuticals | Series A | 20M |
| 4/2000 | Internet Generation Storage | Venture Round | - |
| 12/2009 | moksha8 Pharmaceuticals | Series B | 25.1M |
| 3/2007 | Transcept Pharmaceuticals | Series D | 40M |
| 4/2007 | NovaCardia | Series B | 18M |
| 10/2008 | MAKO Surgical | Post-IPO Equity | 60M |
| 11/2011 | Pivot Medical | Series C | 32M |
| 8/2008 | Glaukos | Series D | 35M |
| 2/2004 | NeurogesX | Series C | 35M |
| 12/2005 | Asthmatx | Series C | 27M |
| 8/2005 | KFx Medical | Series A | 6.2M |
| 6/2016 | SI-BONE | Venture Round | 26M |
| 6/2022 | KEO World | Venture Round | 0 |
| 10/2002 | Peninsula Pharmaceuticals | Series B | 0 |
| 2/2014 | Mindbody Business | Private Equity Round | 50M |
| 4/2005 | SkinMedica | Series E | 0 |
| 4/2006 | SkinMedica | Series E | 0 |
| 9/2007 | Novalar Pharmaceuticals | Series D | 30M |
| 4/2005 | Orexigen Therapeutics | Series B | 35M |
| 7/2009 | Somaxon Pharmaceuticals | Post-IPO Equity | 6M |
| 5/2014 | Pure Life Renal | Series A | 20M |
| 7/2004 | SkinMedica | Series D | 30M |
| 2/2013 | Glaukos | Series F | 30M |
| 2/2011 | Glaukos | Series E | 0 |
| 4/2006 | Bayhill Therapeutics | Venture Round | 15.8M |
| 7/2015 | Kareo | Series G | 55.4M |
| 6/2004 | Somaxon Pharmaceuticals | Series B | 23M |
| 3/2010 | Pulmonx | Series C | 0 |
| 1/2012 | Pulmonx | Private Equity Round | 0 |
| 6/2010 | Avantis Medical Systems | Debt Financing | 2.8M |
| 5/2019 | Pulmonx | Series G | 0 |
| 2/2007 | Pivot Medical | Series A | 2M |
| 9/2011 | SI-BONE | Venture Round | 16M |
| 6/2009 | NovoStent Corporation | Venture Round | 1.1M |
| 11/2020 | FinPay | Series C | 5M |
| 7/2022 | Tebra | Series B | 0 |
| 6/2022 | KEO World | Venture Round | 0 |
| 3/2022 | FinPay | Series D | 0 |
| 11/2020 | FinPay | Series C | 0 |
| 10/2020 | TigerConnect | Series D | 0 |
| 5/2019 | Pulmonx | Series G | 0 |
| 5/2019 | Crown Laboratories | Private Equity Round | - |
| 10/2018 | GC Aesthetics | Venture Round | 0 |
| 3/2018 | Sonoma Pharmaceuticals | Post-IPO Equity | 0 |
| 7/2017 | Colorescience | Series C | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
